ID   ESO-51
AC   CVCL_2036
SY   ESO51
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 890
DR   BioSample; SAMN03473444
DR   cancercelllines; CVCL_2036
DR   Cell_Model_Passport; SIDM00538
DR   Cosmic; 1599338
DR   Cosmic-CLP; 1503367
DR   DepMap; ACH-001497
DR   DSMZ; ACC-694
DR   DSMZCellDive; ACC-694
DR   ECACC; 11012010
DR   EGA; EGAS00001000978
DR   GDSC; 1503367
DR   GEO; GSM1669777
DR   PharmacoDB; ESO51_346_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54832833
RX   PubMed=20075370;
RX   PubMed=23795680;
RX   PubMed=27397505;
RX   PubMed=27594985;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=20075370).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=3.22%; Native American=0.59%; East Asian, North=0%; East Asian, South=1.07%; South Asian=1.19%; European, North=50.02%; European, South=43.9% (PubMed=30894373).
CC   Derived from site: In situ; Esophagus, distal; UBERON=UBERON_0013473.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ; ECACC; PubMed=20075370
ST   Amelogenin: X (DSMZ; ECACC; PubMed=20075370)
ST   Amelogenin: X,Y (Cosmic-CLP)
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 17,20
ST   D19S433: 12
ST   D21S11: 30,33.2 (DepMap; PubMed=20075370)
ST   D21S11: 33.2 (DSMZ)
ST   D2S1338: 25
ST   D3S1358: 15,16
ST   D5S818: 11
ST   D7S820: 8 (Cosmic-CLP; DepMap; DSMZ; PubMed=20075370)
ST   D7S820: 8.2 (ECACC)
ST   D8S1179: 10 (DSMZ)
ST   D8S1179: 10,11,12 (DepMap; PubMed=20075370)
ST   FGA: 21,22
ST   Penta D: 9,13
ST   Penta E: 17
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14,15
DI   NCIt; C4025; Esophageal adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 31
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27594985; DOI=10.12688/f1000research.7033.1;
RA   Contino G., Eldridge M.D., Secrier M., Bower L., Elliott R.F., Weaver J.,
RA   Lynch A.G., Edwards P.A.W., Fitzgerald R.C.;
RT   "Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.";
RL   F1000Research 5:1336.1-1336.12(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//